M yocardial infarction (MI) is an acute ischemic heart disease and remains a major cause of morbidity and mortality worldwide.
M yocardial infarction (MI) is an acute ischemic heart disease and remains a major cause of morbidity and mortality worldwide. 1 ST-segment-elevation MI (STEMI) is a serious type of MI resulting from rupture of vulnerable atherosclerotic plaques and complete occlusion of the coronary artery. 2 The rupture triggers platelet activation and subsequent thrombotic occlusion and limitation of blood flow to the myocardium, resulting in intense inflammation and cardiomyocyte necrosis. 3 Percutaneous coronary intervention has been shown to result in a substantial improvement of survival and is the preferred method of reperfusion in patients with STEMI over the past decades. 4 However, patients undergoing percutaneous coronary intervention often have distal embolization and microvascular obstruction (referred to as the no-reflow phenomenon) that impair left ventricular function and cause larger infarct size and adverse clinical outcomes. 5 Although there are many factors, such as the size of the ischemic area, the duration of occlusion, and residual collateral blood flow, affecting the no-reflow and STEMI prognosis, ischemiaassociated hypoxic environment-induced distal microvascular embolization is believed to play a critical role in the development of no-reflow. 6, 7 Therefore, a better understanding of the process of coronary distal microvascular embolization in vivo is needed to identify more powerful clinical adverse prognostic factors and new prevention strategies.
MAPKs (mitogen-activated protein kinases), a highly conserved family of Ser/Thr (serine/threonine) protein kinases, are activated in response to abundant stimuli, such as mitogens, cytokines, stress, and reactive oxygen species (ROS).
4 best characterized MAPKs are p38, ERK1/2 (extracellular signal-regulated kinase), JNK1/2 (c-Jun N-terminal kinases), and ERK5, which play critical roles in cardiac hypertrophy, cardiac remodeling after MI, atherosclerosis, and vascular restenosis. 11, 12 p38 in particular has detrimental roles in atherosclerosis, infarct size, cardiac function, inflammatory response, and ventricular remodeling post-MI, 13 and these results are the basis of recent clinical trials assessing p38 inhibitors. 14, 15 Although the roles of p38 in agonist-induced platelet activation have long been studied using specific inhibitors, the function of p38 in platelet activation seems to be controversial. Some researchers reported that p38 specific inhibitors, such as SB202190 16 , SB203580 [16] [17] [18] , or VX-702 19 , have no effect on platelet aggregation induced by low-dose thrombin, 16, 17, 19 collagen, 19 U46619 19 , and VWF (von Willebrand factor), 18 whereas the others showed the inhibitory effects of p38 specific inhibitors on platelet activation induced by thrombin, 20, 21 collagen, 17 U46619 17 , and VWF. 20, 22 Therefore, the real functions of p38 in platelet activation, vascular embolization, and their relationships with clinical outcomes remain unclear.
In this study, we found that the p38α isoform was predominantly expressed in human and mouse platelets. Plateletspecific deletion of p38α impaired thrombosis and hemostasis but ameliorated distal microvascular embolization, inflammatory response, ventricular remodeling, and cardiac function post-MI in mice by disturbing the p38α/MAPK-activated protein kinase 2 (MK2)/HSP27 (heat shock protein 27) and p38α/ cytosolic phospholipases A2 (cPLA2) cascades. Further analyses demonstrated that MAPKs were highly activated in preoperative STEMI platelets, and increased phosphorylation of p38 was found in cases with no-reflow outcomes. The results presented in the study indicated that platelet p38α or MK2 may serve as an efficient target for improvement of clinical outcomes in subjects with STEMI.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results p38α Isoform Is Highly Expressed in Human and Mouse Platelets
There are 4 members of the p38 MAPK family (p38α, p38β, p38γ, and p38δ), which are similar in their amino acid sequence but differ in their expression patterns. However, the expression pattern of p38 isoforms in human and mouse platelets remains unknown. The data presented in Figure 1A and 1B show that p38α is the dominant p38 isoform in human and mouse platelets at both the mRNA (Table I in the online-only Data Supplement) and protein levels.
Megakaryocyte/Platelet-Specific p38α Deletion Has No Effect on the Expression of Other p38 Isoforms and Platelet Counts
To investigate the role of p38α in platelet functions, we generated platelet-specific p38α-deficient mice using p38-floxed mice mated with PF4-cre mice. Polymerase chain reaction was used to genotype PF4-cre
) mice, and platelet-specific p38α deficiency was confirmed by Western blotting ( Figure 1C and 1D ). Deletion of p38α had no effects on the expression of the other 3 p38 isoforms in mouse platelets ( Figure 1D ).
Although the p38 specific inhibitor SB203580 was shown to have no effect on megakaryocytic differentiation, 23 the peripheral platelet counts in p38α f/f and p38α −/− mice were measured. Figure 1E showed that p38α −/− mice had 674.4±112.7×10 9 platelets/L, whereas p38α f/f mice had 691.4±130.3×10
9 platelets/L. The platelet number in p38α −/− mice was ≈p38α f/f mice, conforming that p38α probably was not involved in thrombopoiesis.
Platelet p38α Regulates Hemostasis and Arterial Thrombosis
The functions of platelet p38α in hemostasis and arterial thrombosis in vivo were evaluated by tail bleeding time assays and the FeCl 3 -induced carotid artery thrombosis model. Figure 1F shows that the average bleeding time for p38α f/f mice was 2.613±2.229 minutes compared with 6.083±3.439 minutes in the p38α −/− mice. Figure 1G and Figure IB in the onlineonly Data Supplement shows that the first occlusion time of FeCl 3 -injured carotid artery in p38α f/f mice was 7.470±0.7401 minutes compared with 12.75±2.103 minutes in p38α −/− mice. These results suggest that platelet p38α is important in the regulation of hemostasis and arterial thrombosis.
p38α Deficiency Impairs Platelet Adhesion, Spreading, Aggregation, and Granule Secretion
To further determine the functions of p38α in platelet activation, we assessed platelet adhesion, spreading, granule secretion, and aggregation. The data presented in Figure 2A and Figure  IIA in the online-only Data Supplement show that the aggregation levels were diminished in p38α −/− platelets in response to collagen and ADP but not thrombin or U46619 stimulation.
Platelet activation induced by agonists promotes granule secretion and integrin activation (inside-out signal). Here, platelet α-granule secretion and integrin αIIbβ3 activation were analyzed by detecting the mean fluorescence intensity of P-selectin expression and Fg binding induced by ADP or thrombin, respectively. Both relative mean fluorescence intensity values were dramatically reduced in p38α −/− platelets stimulated by ADP but not by thrombin ( Figure 2B and 2C) .
Platelet adhesion and accumulation at the injury site under shear force was initiated and detected by recognizing exposed collagen. 24 To investigate the effects of p38α on platelet adhesion and aggregation, we labeled the whole blood from p38α platelets, which showed that p38α −/− platelets had defects in adhesion and aggregation on collagen under flow ( Figure 2D ).
Integrin αIIbβ3-mediated outside-in signaling is a key amplifying step for thrombus growth and stability. 25 The functions of p38α on integrin αIIbβ3-mediated outside-in signaling were assayed by platelet spreading on immobilized Fg and clot retraction. As shown in Figure 2E , the clot retraction ratio in p38α f/f platelets was 0.7821±0.06108 versus 0.6395±0.05057 in p38α −/− platelets. Figure 2F shows that the average size of spread platelets in p38α f/f was 1432±135.3 versus 822.4±364.3 in p38α −/− platelets. These results indicated that p38α is involved in regulating integrin αIIbβ3-mediated outside-in signaling during platelet activation.
Taken together, these results suggest that p38α deficiency impaired platelet adhesion, spreading, aggregation, and granule secretion.
ERK1/2 and ERK5 Partially Compensate for p38α Deficiency-Caused Decreases in Receptor-Mediated Platelet Activation
Previous studies have shown that the members of the MAPK family crosstalk with each other. Several studies have reported that p38 negatively regulates ERK1/2 activation because pharmacological inhibition of p38 improves ERK1/2 activity. 26 Additionally, phosphorylated p38 was shown to directly interact with ERK1/2 and prevent it from being phosphorylated by MEK1/2 (mitogen-activated protein kinase kinase). 27 In our study, we found that p38α deficiency had no effects on the expression of ERK1/2, JNK, and ERK5 ( Figure 3A ; Figure  IIIA in the online-only Data Supplement). However, the phosphorylation levels of ERK1/2 and its upstream kinase MEK1/2 was significantly enhanced in p38α −/− platelets stimulated with collagen, ADP, thrombin, and U46619 ( Figure 3B ; Figure IIIB in the online-only Data Supplement). In addition, the ERK1/2 upstream kinase MEK1/2 inhibitor U0126 synergistically inhibited aggregation of p38α −/− platelets in response to collagen, ADP, thrombin, and U46619 ( Figure 3C ), suggesting that MEK1/2-ERK1/2 have a compensatory function on p38α
In addition, the phosphorylation of ERK5 was also significantly enhanced in p38α −/− platelets stimulated with thrombin and U46619, but not collagen or ADP ( Figure 3B ; Figure  IIIB in the online-only Data Supplement). Cameron et al 28 recently showed that ERK5 activation is also agonist specific, and ERK5 deficiency alters platelet activation induced by thrombin and U46619, but not collagen and ADP. These compensatory activation of ERK5 may partially interpret stimuli specific effects of p38α deficiency on platelet activation.
MK2/HSP27 and cPLA2 Are Major Pathways Regulated by p38α During Receptor-Mediated Platelet Activation
There are dozens of substrates of p38 that regulate multiple cellular processes. Among them, MK2 and cPLA2 were −/− mice have defects in hemostasis and arterial thrombosis. A, The mRNA levels of p38 isoforms in both human platelets (H-PLT) and mouse platelets (M-PLT). All data were normalized to GAPDH first and then p38α (n=4). B, The protein levels of p38 isoforms in both H-PLT and M-PLT. HEK293 (human embryonic kidney 293 cells) whole-cell lysate was used as a positive control for human p38. M-+ is the positive control prepared from wild-type mouse tissues; for p38α and p38β, the protein sample was from the liver; for p38γ, the protein sample was from the heart; for p38δ, the protein sample was from the small intestine. , and p38α −/− mice. M-+ is the positive control prepared from wild-type mouse tissues; for p38α and p38β, the protein sample was from the liver; for p38γ, the protein sample was from the heart; for p38δ, the protein sample was from the small intestine. E, The platelet counts in p38α f/f and p38α shown to be major downstream substrates of p38. 29, 30 MK2 amplifies signals by regulating many factors, including HSP27, 29 lymphocyte-specific protein 1, and transcription factors. 31 cPLA2 is an enzyme that produces lysophospholipids, releases arachidonic acid and is implicated in diverse cellular responses, such as mitogenesis and inflammation. perfused over a collagen-coated surface at a shear rate of 1500 s −1 (n=12; ***P<0.001). E, Clot retraction of p38α f/f and p38α −/− mouse platelets in human plasma (n=4; *P<0.05). F, The spreading of p38α f/f and p38α −/− mouse platelets on immobilized Fg (n=16; ***P<0.001). FITC indicates fluorescein isothiocyanate; and MFI, mean fluorescent intensity. e189 and the p38α-specific inhibitor LY2228820 completely blocked the phosphorylation of MK2, HSP27, and cPLA2 in human platelets stimulated by collagen, ADP, thrombin, and U46619. However, the MEK1/2 inhibitor U0126 and the ERK5 inhibitor XMD8-92, but not the JNK inhibitor SP600125, partially blocked the phosphorylation of MK2, HSP27, and cPLA2, suggesting that ERK1/2 and ERK5, but not JNKs, synergistically regulate the p38α/MK2/HSP27 and p38α/cPLA2 pathways in human platelets.
A MK2-specific inhibitor, MK-25, was used to investigate the role of MK2 in platelet activation. Figure 4B shows that MK-25 suppressed human platelet aggregation induced by collagen, ADP, and U46619, but not thrombin, in a dose-dependent manner. Furthermore, the phosphorylation of HSP27, but not Figure 4C ). Additionally, MK-25 suppressed human platelet spreading on immobilized Fg in a dose-dependent manner ( Figure 4D) . A previous study reported that HSP27 inactivation disrupts actin polymerization and reorganization. 33 To clarify the function of the p38α/ MK2/HSP27 pathway in αIIbβ3-mediated cytoskeleton reorganization, we stained F-actin in CHO cells expressing human αIIbβ3 and allowed them to spread on Fg in presence or absence of MK-25. Figure 4E demonstrates that MK-25 dosedependently disrupted the formation of actin bundles.
Similar to human platelets, MK-25 inhibited p38α f/f platelet aggregation in response to collagen and ADP and spreading on immobilized Fg (Figure 4F and 4H) . The absence of MK2 expression in p38α −/− platelets ( Figure 4G ) confirmed the results of a previous report that MK2 expression is regulated by p38. 34 The decreased phosphorylation of cPLA2 in p38α −/− platelets stimulated with agonist collagen and ADP suggested that in addition to p38α/MK2/HSP27, the p38α/cPLA2 pathway is also important in regulating mouse platelet activation ( Figure 4I ).
These results suggest that MK2/HSP27 and cPLA2 are major pathways regulated by p38α during agonist-mediated platelet activation.
p38α Is Also a Prodromal Sensor of ROS in Platelets and Manipulates ROS-Induced Platelet Activation
When MI occurs, ROS are acutely produced in the ischemic microenvironment and are major mediators of distal embolization, microvascular obstruction, and inflammatory response. 35 To determine whether platelet MAPKs are activated by redox stress, we incubated platelets with H 2 O 2 (1 type of ROS). The phosphorylation levels of p38, MK2, cPLA2, ERK1/2, and ERK5, but not JNKs, were significantly enhanced in both human platelets and p38α f/f mouse platelets in response to H 2 O 2 in a doseand time-dependent manner, and p38 activation was the earliest event in response to H 2 O 2 stimulation (Figure 5A through 5D ). H 2 O 2 -induced phosphorylation of MK2 and cPLA2 was greatly diminished in p38α −/− mouse platelets or in p38α f/f mouse and human platelets treated with LY2228820 ( Figure 5C through  5E) . Surprisingly, H 2 O 2 -induced ERK1/2 phosphorylation was also substantially attenuated in p38α −/− mouse platelets, indicating that in response to ROS, ERK1/2 may also function as a downstream effecter of p38α ( Figure 5C and 5D ).
It was reported that H 2 O 2 alone did not affect platelet aggregation. 36 H 2 O 2 dose-dependently promoted low-level thrombin-induced p38α f/f and human platelet aggregation (Figure 5F and 5G), suggesting that the ischemic microenvironment could facilitate platelet activation. The aggregation of p38α −/− platelets in response to thrombin plus H 2 O 2 was diminished ( Figure 5F ), indicating that p38α deficiency resulted in platelet insensitivity to ROS. LY2228820, U0126, and XMD8-92, but not SP600125, strongly attenuated H 2 O 2 -facilitated thrombininduced p38α f/f mouse and human platelet aggregation, further demonstrating that JNKs are not involved in ROS-dependent platelet activation ( Figure 5H ). Interestingly, both MK-25 and the cyclooxygenase inhibitor aspirin inhibited H 2 O 2 -induced platelet aggregation, suggesting that MK2 and cPLA2/cyclooxygenase are effective therapeutic targets for prevention of ROS-induced platelet activation.
Cardiac Function of p38α −/− Mice Post-MI Is Improved
Because p38 plays a key role in ROS-induced platelet activation, we propose that p38 plays a role in the ischemic environment, resulting in microvascular obstruction and inflammatory response. A MI model (the left anterior descending artery [LAD] coronary artery was permanently ligated) was established.
LAD coronary ligation induces transmural ischemia as shown by ST-segment elevation on the ECG in both mice (data not shown). Figure 6A shows the echocardiograms of hearts of sham p38α f/f and p38α −/− mice on day 7, and there was no difference in cardiac functions between the 2 groups. However, hearts from MI p38α f/f mice showed increased dilation, congestion, and remodeling in comparison with MI p38α −/− mouse hearts (Figure 6A and 6B −/− mice with 2.45±0.285 and 3.54±0.279, respectively. To evaluate the roles of platelet p38α in inflammatory response, and microthrombus in the peri-infarct zone, we immunostained heart sections from p38α f/f and p38α −/− mice with the leukocyte marker CD45 and platelet-specific marker CD42c on day 3 post-MI. Figure 6D and 6E show that p38α −/− mice had decreased leukocyte infiltration and microthrombi. In mRNA level (Table II in the online-only Data Supplement), the heart failure biomarkers (BNP [B-type natriuretic peptide], β-MHC [β-isoform of myosin heavy chain], and atrial natriuretic factor), 37 cytokines CXCL2 (chemokine (C-X-C motif) ligand 2) and CCL2 (chemokine (C-C motif) ligand 2), 38 and remodeling related molecules collagen I, fibronectin, and cadherin 3 39 were all upregulated in post-MI day 1 p38α f/f heart, but lower in p38α −/− mice heart (Figure IVC through IVE in the online-only Data Supplement). Additionally, the infarction area and spread distance of p38α f/f mice were larger and further, respectively, than those of p38α −/− mice ( Figure 6C ). And the TUNEL (TdTmediated dUTP nick-end labeling) assays further showed that myocardial apoptosis of p38α −/− mice is much lower than that of p38α f/f mice ( Figure IVF in the online-only Data Supplement). Figure 6F and Figure IIID in the online-only Data Supplement showed that LAD ligation significantly enhanced the phosphorylation levels of p38, MK2, cPLA2, ERK1/2, and ERK5 in p38α f/f mouse platelets isolated on day 3 and day 7 in comparison with those of sham p38α f/f mice, and p38α deficiency substantially attenuated LAD-facilitated platelet activation and LAD ligation-induced phosphorylation of MK2, cPLA2, and ERK1/2. These results demonstrate that p38α regulates MK2, cPLA2, and ERK1/2 activation in platelets in the post-MI ischemic environment in vivo.
In conclusion, by activating MK2/HSP27 and cPLA2 downstream, platelet p38α plays a detrimental role in e191 receptor-and ROS-mediated platelet activation and MI deterioration ( Figure 6G ).
MAPKs Are Activated in Platelets From Patients With STEMI, and Higher Phosphorylation Levels of p38 Is Associated With No-Reflow
To evaluate the status of MAPK activation in platelets from patients with STEMI, we measured the phosphorylation levels of MAPKs in platelets from the 40 patients with STEMI and 21 healthy subjects by immunoblotting. As shown in Figure  V in the online-only Data Supplement, the phosphorylation levels of MAPKs were significantly upregulated in STEMI patient platelets. In particular, the average relative levels of phospho-p38 in platelets from patients with STEMI were 0.6433±0.2880 versus 0.1928±0.1828 in healthy subjects, 0.8564±0.6862 for phospho-ERK2 in STEMI platelets versus 0.2554±0.1045 in healthy subjects, 0.8477±0.4007 for phospho-JNK2 in STEMI platelets versus 0.5279±0.2885 in healthy subjects, and 0.1214±0.0875 for phospho-ERK5 in STEMI platelets versus 0.0652±0.0397 in healthy subjects. Taken together, the results indicated that MAPKs are activated in platelets from patients with STEMI. 
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Correlation analysis was also performed to clarify the relationship between the relative phosphorylation levels of MAPKs in platelets and clinical characteristics of patients with STEMI. The data in the Table showed that the phosphorylation levels of p38 and JNK2 were significantly increased in cases with thrombus aspiration. Additionally, the phosphorylation levels of p38 in platelets were significantly increased in patients with no-reflow. Although effective thrombus aspiration can acutely f/f and p38α −/− mice in the sham group and LAD coronary ligation group on day 7 after surgery (n=5; ***P<0.001, and **P<0.01). C, Masson trichrome staining of heart sections from p38α f/f and p38α −/− mice and quantification of infarct size (mean % of left ventricle [LV] area, n=5; ***P<0.001). D, The representative images of immunostaining CD45 and relative white blood cell (WBC) counts per high power field (HPF) in heart sections from p38α f/f and p38α −/− mice on day 3 post-MI (n=5; **P<0.01). E, Representative images of immunostaining of CD42c and relative platelet counts per HPF in heart sections from p38α f/f and p38α −/− mice on day 3 post-MI (n=5; ***P<0.001). F, The phosphorylation and total levels of p38, MK2, cPLA2, ERK1/2, ERK5, and JNKs in p38α f/f and p38α −/− platelets obtained from the corresponding mice on day 3 and 7 post-MI. G, A diagram of proposed p38 signaling pathway in platelet activation and MI deterioration. ERK indicates extracellular signal-regulated kinase; IVS, interventricular septal; JNK, c-Jun N-terminal kinases; LVEIDd, left ventricular internal diameter end diastole; LVEIDs, left ventricular internal diameter end systole; and PW, posterior wall. e193 decrease the thrombus burden and restore myocardial reperfusion, the usage of thrombus-aspirating device also reflects patients with a large thrombus burden and highly thrombotic lesions in a large vessel. 40 The no-reflow phenomenon is the major reason for the increase in mortality after percutaneous coronary intervention , primarily because of distal embolization and microvascular obstruction. 41 Therefore, hyperactivation of p38 is likely associated with no-reflow.
Discussion
MI-derived ROS induce platelet activation, which can result in an adverse prognosis in acute myocardial infarction. 42 More recently, Cameron et al 28 reported that ERK5 functions as a platelet activator in ischemic conditions, leading to microvascular embolization and MI expansion in mice. In our study, the results demonstrated that platelet MAPKs, including ERK5, are activated in response to hypoxic environments in vitro and in vivo. However, among MAPKs, p38 serves as a prodromal sensor of low levels of ROS in platelets and is constitutively activated. Moreover, the average phosphorylation levels of MAPKs, including ERK5, were enhanced in platelets from preoperative patients with STEMI. Notably, higher levels of phospho-p38 were related to the no-reflow phenomenon, which indicated that p38 plays a crucial role in the MI process.
Furthermore, we found that p38α is a dominant isoform of p38 in platelets. The inhibitors of p38α, MEK1/2, and ERK5, but not JNK, substantially blocked H 2 O 2 -facilitated thrombininduced platelet aggregation, suggesting that p38α, ERK1/2, and ERK5 are the major MAPKs that are activated in platelets in response to ROS. Although ERK1/2 has compensatory effects on receptor-mediated platelet aggregation in the absence of p38α, ERK1/2 activation is specifically dependent on the presence and activation of p38α in ROS-induced platelet activation, implying that ERK1/2 may not be the direct ROS response molecules in platelets. p38α deficiency abolished hypoxic condition (1% O 2 )-induced activation of p38, MK2, cPLA2, and slightly suppressed hypoxia-induced ROS production in platelet ( Figure IVA and IVB in the online-only Data Supplement), suggesting p38α plays critical roles in hypoxiamediated platelets ROS generation and activation. p38α deficiency significantly inhibited ischemia-induced platelet activation and improved distal microvascular embolization and cardiac function in a chronic mouse MI model, further suggesting that p38α is a replaceable intracellular mediator of platelet activation in response to post-MI hypoxic environments.
MK2 was shown to be an essential substrate of p38 in regulating inflammation, cell division, differentiation, apoptosis, and cell motility. 31, 43 In addition, HSP27, as a potential MK2 substrate, 44, 45 is phosphorylated and translocated from the cytoplasm to the assembling cytoskeleton to control actin polymerization during the platelet morphological change and subsequent aggregation. 44, 45 Here, we found that HSP27 phosphorylation was completely suppressed by inhibitors of p38α or MK2 in human platelets in response to receptor agonists and H 2 O 2 . Analysis of the intracellular mechanism showed that integrin αIIbβ3-mediated assembly of actin filaments was significantly destroyed by the MK2 inhibitor MK-25 in cells spreading on Fg, implying that the p38α/MK2/HSP27 pathway modulates platelet activation by regulating actin cytoskeleton reorganization. MK-25 completely eliminated H 2 O 2 -induced platelet activation, further indicating that p38α/ MK2/HSP27 is an important pathway in platelets in response to post-MI hypoxic environments.
Naik et al 46 recently identified Ask1 as the upstream regulator of p38 in receptor-mediated platelet activation, and Ask1 deficiency impaired platelet functions in part because of failure of p38-dependent activation of cPLA2. cPLA2 is a phospholipase that catalyzes glycerophospholipid hydrolysis to release arachidonic acid. Then, cyclooxygenases convert arachidonic acid to prostaglandin H2, which is a substrate for several isomerases that generate different bioactive prostanoids, including TxA2 and its stable hydration product TxB2 in platelets. 30 cPLA2α deficiency in mice has been reported to reduce inflammation, decrease infarct size, and improve left ventricle function by suppressing the production of arachidonic acid and TxB 2 after ischemia/reperfusion injury. 47 Here, we demonstrated that receptor-mediated or ROS-induced cPLA2 phosphorylation was intensively suppressed by p38α deletion or inhibition, although inhibition of ERK1/2 and ERK5 also slightly blocked cPLA2 phosphorylation. The cyclooxygenase inhibitor aspirin almost completely attenuated H 2 O 2 -facilitated platelet activation, implying that the platelet p38α/cPLA2/cyclooxygenase axis is a critical pathway involved in hypoxia-induced cardiac distal microvascular embolization, inflammatory response, and dysfunction.
Dual antiplatelet therapy (the cyclooxygenase inhibitor aspirin plus ADP receptor P2Y12 inhibitors) is the first-line treatment for STEMI. 48 However, a significant number of patients with STEMI develop no-reflow after percutaneous coronary intervention even when high doses of antiplatelet medications are administered. 49 Although clinical trials of p38 inhibitors, such as losmapimod or SB203580, in patients with acute myocardial infarction have been performed, the efficacy of these inhibitors in protecting myocardium from ischemic injuries remains controversial. 15, [50] [51] [52] In our study, p38α deficiency specifically abated collagen-or ADP-induced platelet aggregation, secretion, and integrin αIIbβ3-mediated adhesion, implying that p38α is a potential new antithrombotic target. More importantly, p38α deficiency specifically suppressed platelet reactivity in ischemic states by restraining redox-induced activation of cPLA2/cyclooxygenase and MK2/HSP27 pathways ( Figure 6G ), thereby attenuating inflammatory response and myocardial remodeling during the postinfarct period. Therefore, specific inhibition of platelet p38α or its downstream MK2 may also serve as a new potential therapeutic strategy for prevention of myocardial injury post-MI.
